ADDISON, Texas, March 11, 2015 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) announced today the extension to December 31, 2015 of the option granted to OraDisc GmbH for the use of our OraDisc technology for drug delivery. The therapeutic categories covered by the agreement have been expanded to include anti-psychotics, neurologics and erectile dysfunction.
The global drug delivery market expanded from $127 billion in 2010 to $143 billion in 2012 with anticipated growth to $224 billion in 2017. The market for transmucosal drug delivery is approximately 4% of the global drug delivery market with a forecast of approximately $9.0 billion in 2017.
The OraDisc technology is a unique, patent protected multi-layer mucoadhesive drug delivery technology designed to delivery drugs systemically across the mucosal surface.
OraDisc causes minimum discomfort, is easy to apply and capable of providing tailored erosion rates to delivery therapeutics over different time intervals. The erosion time can be easily regulated, from 15 minutes to over three hours, simply by compositional changes and /or coating thickness.
Development activities have commenced with four compounds that have recently lost patent protection or the patent will expire within the next 24 months. One potential advantage of the OraDisc technology is to extend the period of patent protection.
Upon patent expiration, products experience a decrease in sales between 70% to 80% due to the generic competition. The selected development candidates are compounds which are block busters in their therapeutic categories; antipsychotic, neurologics, erectile dysfunction and analgesics.
The global erectile dysfunction drug market is valued at approximately $4.3 billion. The chosen candidates within the psychotic and neurologic market currently have annual sales of approximately $7.5 billion and $4.0 billion.
Commenting on the option extension, Dr. Josef Doppler, Director of OraDisc GmbH stated “Extensive review has been undertaken with potential strategic partners and the medical community to identify the appropriate therapeutic categories and actives to take maximum advantage of the OraDisc technology. We are excited with the potential to develop a range of products utilizing this mucoadhesive drug delivery technology. Development programs have been initiated to move these projects forward.”
Studies have been conducted which demonstrate the effectiveness of the OraDisc technology as a drug delivery vehicle. Compared to oral tablet formulations in preclinical studies OraDisc was able to achieve at equal doses a maximum blood concentration 80% higher and deliver in excess of 130% more drug in the same time period. In addition, depending on the formulation characteristics used drug delivery can be easily regulated. These characteristics plus rapid onset of drug action and avoidance of first pass metabolism make the OraDisc technology well suited to the chosen therapeutic categories with the potential for superior clinical performance.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
ULURU Inc. (OTCQB: ULUR) trades on the OTCQB Venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the advantages of the OraDisc technology, regulation of drug delivery , potential to develop a range of products and the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uluru-inc-announces-the-extension-and-expansion-of-the-option-granted-to-oradisc-gmbh-300049076.html
SOURCE ULURU Inc.
Help employers find you! Check out all the jobs and post your resume.
